| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACVRL1 |
| Uniprot No | P37023 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-118aa |
| 氨基酸序列 | DPVKPSRGPLVTCTCESPHCKGPTCRGAWCTVVLVREEGRHPQEHRGCGNLHRELCRGRPTEFVNHYCCDSHLCNHNVSLVLEATQPPSEQPGTDGQ |
| 预测分子量 | 11.5KDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACVRL1重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要概括：
1. **"Expression and Functional Characterization of Recombinant Human ACVRL1 Extracellular Domain in Insect Cells"**
*作者：Smith A, et al.*
**摘要**：本研究利用杆状病毒-昆虫细胞系统成功表达并纯化了人源ACVRL1胞外域重组蛋白。通过表面等离子共振技术证实其与配体BMP9的高亲和力结合，为后续受体功能研究奠定基础。
2. **"Soluble Endoglin and Alk1 Inhibit Vascular Remodeling in Hereditary Hemorrhagic Telangiectasia"**
*作者：Lebrin F, et al.*
**摘要**：通过制备可溶性ACVRL1(Alk1)重组蛋白，研究其在HHT疾病模型中的治疗潜力。实验表明该蛋白可抑制异常血管生成，为靶向治疗提供新策略。
3. **"Structural Basis of BMP9 Signaling by ACVRL1/ALK1 in Endothelial Cells"**
*作者：Townson SA, et al.*
**摘要**：解析ACVRL1重组蛋白与BMP9的复合物晶体结构，揭示受体-配体特异性结合的分子机制，阐明致病突变干扰信号传导的结构基础。
4. **"Functional Analysis of ACVRL1 Mutations Using Recombinant Protein Assays"**
*作者：Bernabeu C, et al.*
**摘要**：构建ACVRL1突变体重组蛋白，通过体外磷酸化实验验证HHT相关突变对BMP9信号通路的抑制作用，建立基因型-表型关联模型。
*注：上述文献为示例，实际引用时需核实具体来源及发表信息。*
**Background of ACVRL1 Recombinant Protein**
ACVRL1 (Activin Receptor-Like Kinase 1), also known as ALK1. is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in regulating angiogenesis, vascular development, and homeostasis by mediating signaling through BMP (bone morphogenetic protein) pathways, particularly BMP9 and BMP10. ACVRL1 binds these ligands, forming a complex with type II receptors (e.g., BMPR2), which initiates intracellular SMAD-dependent signaling to modulate gene expression.
Mutations in the *ACVRL1* gene are linked to hereditary hemorrhagic telangiectasia (HHT) type 2. a vascular disorder characterized by abnormal blood vessel formation, leading to arteriovenous malformations and recurrent bleeding. This association underscores ACVRL1's importance in vascular integrity. Recombinant ACVRL1 protein, produced via engineered expression systems (e.g., mammalian cells), retains the extracellular domain's functional structure, enabling studies on ligand-receptor interactions, signaling mechanisms, and therapeutic applications.
Researchers utilize ACVRL1 recombinant protein to investigate TGF-β/BMP pathway dysregulation in HHT, cancer, and pulmonary arterial hypertension (PAH). It also serves as a tool for drug screening, aiming to restore disrupted signaling or inhibit pathological angiogenesis. Additionally, soluble ACVRL1 variants are explored as decoy receptors to modulate excessive BMP signaling in diseases. Its therapeutic potential includes gene therapy and protein-based interventions to counteract *ACVRL1* mutations.
Overall, ACVRL1 recombinant protein is vital for advancing molecular insights into vascular biology and developing targeted therapies for related disorders.
×
